BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 28188501)

  • 21. Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.
    Bosch DJ; Wang D; Nijsten MW; Mul VE; Hospers GA; Burgerhof JG; Struys MM; Plukker JT
    Am J Surg; 2016 Jul; 212(1):89-95. PubMed ID: 27036621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Luc G; Gronnier C; Lebreton G; Brigand C; Mabrut JY; Bail JP; Meunier B; Collet D; Mariette C
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1357-64. PubMed ID: 26014152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
    Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
    Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 26. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of lymphovascular invasion in patients with esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
    Chen WH; Huang YL; Chao YK; Yeh CJ; Chang HK; Tseng CK; Liu YH
    Ann Surg Oncol; 2015 Jan; 22(1):338-43. PubMed ID: 25023545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
    Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
    Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
    Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
    JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 32. REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.
    Sato Y; Motoyama S; Nanjo H; Ito S; Yoshino K; Sasaki T; Kuribayashi K; Nagaki Y; Imai K; Saito H; Minamiya Y; Ogawa J
    Ann Surg Oncol; 2013 Sep; 20(9):3044-51. PubMed ID: 23645481
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Age and Comorbidity on Choice and Outcome of Two Different Treatment Options for Patients with Potentially Curable Esophageal Cancer.
    Faiz Z; van Putten M; Verhoeven RHA; van Sandick JW; Nieuwenhuijzen GAP; van der Sangen MJC; Lemmens VEPP; Wijnhoven BPL; Plukker JTM
    Ann Surg Oncol; 2019 Apr; 26(4):986-995. PubMed ID: 30719634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
    Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
    Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08).
    Ruhstaller T; Thuss-Patience P; Hayoz S; Schacher S; Knorrenschild JR; Schnider A; Plasswilm L; Budach W; Eisterer W; Hawle H; Mariette C; Hess V; Mingrone W; Montemurro M; Girschikofsky M; Schmidt SC; Bitzer M; Bedenne L; Brauchli P; Stahl M; ; ; ;
    Ann Oncol; 2018 Jun; 29(6):1386-1393. PubMed ID: 29635438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of neoadjuvant chemoradiotherapy in clinical T2N0M0 esophageal cancer: A population-based cohort study.
    Goense L; Visser E; Haj Mohammad N; Mook S; Verhoeven RHA; Meijer GJ; van Rossum PSN; Ruurda JP; van Hillegersberg R
    Eur J Surg Oncol; 2018 May; 44(5):620-625. PubMed ID: 29478739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Spierings LE; Lagarde SM; van Oijen MG; Gisbertz SS; Wilmink JW; Hulshof MC; Meijer SL; Anderegg MC; van Berge Henegouwen MI; van Laarhoven HW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S766-71. PubMed ID: 26350367
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemoradiotherapy before and after surgery for locally advanced esophageal cancer: a SEER-Medicare analysis.
    Hong JC; Murphy JD; Wang SJ; Koong AC; Chang DT
    Ann Surg Oncol; 2013 Nov; 20(12):3999-4007. PubMed ID: 23800897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Prognostic Scoring Model for the Utility of Induction Chemotherapy Prior to Neoadjuvant Chemoradiotherapy in Esophageal Cancer.
    Xi M; Liao Z; Deng W; Xu C; Komaki R; Blum M; Hofstetter WL; Ho L; Lin SH
    J Thorac Oncol; 2017 Jun; 12(6):1001-1010. PubMed ID: 28351804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.